title: Cancer Drugs Fund 2.0: A Missed Opportunity?
authors.affiliation: Department of Emergency Medicine, University of Alberta, Suite 736 University Terrace, 8303 112 Street, Edmonton, AB, T6G 1K4, Canada. mccabe1@ualberta.ca.
authors.forename: Christopher
authors.initials: C
authors.lastname: McCabe
authors.affiliation: London Borough of Wandsworth, London, UK.
authors.forename: Ash
authors.initials: A
authors.lastname: Paul
authors.affiliation: Sheffield City Council, Room 209, Town Hall, Sheffield, S1 2HH, UK.
authors.forename: Greg
authors.initials: G
authors.lastname: Fell
authors.affiliation: Department of Emergency Medicine, University of Alberta, Suite 736 University Terrace, 8303 112 Street, Edmonton, AB, T6G 1K4, Canada.
authors.forename: Mike
authors.initials: M
authors.lastname: Paulden
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics*; D017277:Drug Approval; D016527:Drug Costs; D005376:Financial Management; D006801:Humans; D007880:Legislation, Drug; D009369:Neoplasms / Q000188:drug therapy / Q000191:economics*; D013222:State Medicine / Q000191:economics*
chemical_list: D000970:Antineoplastic Agents